Myrto Nikoloudaki

Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus

Christina Adamichou, Irini Genitsaridi, Dionysis Nikolopoulos et al. · Annals of the Rheumatic Diseases · 2021 · 115 citations · Full text

Computing, Biostatistics, Immunology +17

Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression

Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis et al. · Annals of the Rheumatic Diseases · 2024 · 35 citations · Full text

Medicine, Internal Medicine, Frailty +14

Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study

Myrto Nikoloudaki, Dionysis Nikolopoulos, Sofia Koutsoviti et al. · Frontiers in Immunology · 2023 · 25 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events

Dionysis Nikolopoulos, Catherine Loukogiannaki, George Sentis et al. · Annals of the Rheumatic Diseases · 2024 · 23 citations · Full text

Life Sciences, Immunology, Molecular Biology +16

Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways

Georgia-Savina Moysidou, Panagiotis Garantziotis, George Sentis et al. · Annals of the Rheumatic Diseases · 2024 · 23 citations · Full text

Life Sciences, Immunology, Molecular Biology +17